生物工程化凝血因子VIII变异体3.2 Å结构揭示C2结构域两种构象
本研究通过X射线晶体学和串联质谱糖蛋白组学表征了人/猪嵌合B结构域缺失的FVIII构建体ET3i,获得3.2 Å晶体结构,观察到晶体中两个FVIII分子的C2结构域存在两种构象,并以此改进模型优化了分辨率较低的人FVIII结构。
要点
- ET3i的3.2 Å晶体结构与人类FVIII高度保守,展示了A2结构域与其余结构的界面细节。
- 晶体中两个FVIII分子显示C2结构域相对于其余结构存在两种构象。
- 改进的结构模型为开发更长半衰期、更高表达和更低免疫原性的FVIII疗法提供基础。
核心结论
- ET3i的3.2 Å晶体结构与人FVIII高度保守,并揭示C2结构域两种构象,改进的结构模型有助于下一代FVIII工程化开发。
研究设计与样本
- 采用X射线晶体学和基于串联质谱的糖蛋白组学表征人/猪嵌合B结构域缺失的FVIII异二聚体ET3i。
- ET3i是经凝血酶蛋白水解激活后具有改善表达和较慢A2结构域解离的构建体。
主要发现
- 报道了ET3i的3.2 Å晶体结构,并用LC-MS/MS糖蛋白组学表征了N连接聚糖的分布。
- 结构显示与人类FVIII蛋白高度保守,并提供了A2结构域与其余FVIII结构之间界面的详细视图。
- 晶体中两个FVIII分子观察到C2结构域相对于其余FVIII结构的两种构象。
- 利用ET3i改进的模型和立体化学作为支架,生成了改进的人FVIII精修结构,原始数据集分辨率为3.7 Å和4.0 Å,新结构改善了精修统计。
临床怎么用
- 该结构信息可支持下一代FVIII治疗药物的工程化改造,目标包括更长半衰期、更高表达水平和更低免疫原性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coagulation factor VIII represents one of the oldest protein-based therapeutics, serving as an effective hemophilia A treatment for half a century. Optimal treatment consists of repeated intravenous infusions of blood coagulation factor VIII (FVIII) per week for life. Despite overall treatment success, significant limitations remain, including treatment invasiveness, duration, immunogenicity, and cost. These issues have inspired research into the development of bioengineered FVIII products and gene therapies. OBJECTIVES: To structurally characterize a bioengineered construct of FVIII, termed ET3i, which is a human/porcine chimeric B domain-deleted heterodimer with improved expression and slower A2 domain dissociation following proteolytic activation by thrombin. METHODS: The structure of ET3i was characterized with X-ray crystallography and tandem mass spectrometry-based glycoproteomics. RESULTS: Here, we report the 3.2 Å crystal structure of ET3i and characterize the distribution of N-linked glycans with LC-MS/MS glycoproteomics. This structure shows remarkable conservation with the human FVIII protein and provides a detailed view of the interface between the A2 domain and the remaining FVIII structure. With two FVIII molecules in the crystal, we observe two conformations of the C2 domain relative to the remaining FVIII structure. The improved model and stereochemistry of ET3i served as a scaffold to generate an improved, refined structure of human FVIII. With the original datasets at 3.7 Å and 4.0 Å resolution, this new structure resulted in improved refinement statistics. CONCLUSIONS: These improved structures yield a more confident model for next-generation engineering efforts to develop FVIII therapeutics with longer half-lives, higher expression levels, and lower immunogenicity.
引用
- Smith IW, d'Aquino AE, Coyle CW, et al. The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain. J Thromb Haemost. 2019. PMID: 31454152. doi:10.1111/jth.14621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。